Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/61704
Registo completo
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Vieira, Raquel | por |
dc.contributor.author | Souto, Selma B. | por |
dc.contributor.author | Sánchez-López, Elena | por |
dc.contributor.author | López Machado, Ana | por |
dc.contributor.author | Severino, Patricia | por |
dc.contributor.author | Jose, Sajan | por |
dc.contributor.author | Santini, Antonello | por |
dc.contributor.author | Silva, Amelia M. | por |
dc.contributor.author | Fortuna, Ana | por |
dc.contributor.author | García, Maria Luisa | por |
dc.contributor.author | Souto, Eliana B. | por |
dc.date.accessioned | 2019-10-10T15:31:46Z | - |
dc.date.available | 2019-10-10T15:31:46Z | - |
dc.date.issued | 2019-08-28 | - |
dc.identifier.citation | Vieira, Raquel; Souto, Selma B.; Sánchez-López, Elena; López Machado, Ana; Severino, Patricia; Jose, Sajan; Santini, Antonello; Silva, Amelia M.; Fortuna, Ana; García, Maria Luisa; Souto, Eliana, Sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndromestrategies for in vivo administration: Part-II. Journal of Clinical Medicine, 8(9), 1332, 2019 | por |
dc.identifier.issn | 2077-0383 | por |
dc.identifier.uri | https://hdl.handle.net/1822/61704 | - |
dc.description.abstract | Diabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic ß-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed. | por |
dc.description.sponsorship | The authors acknowledge the financial support received from Portuguese Science and TechnologyFoundation (FCT/MCT) and from European Funds (PRODER/COMPETE) under the project referenceM-ERA-NET/0004/2015-PAIRED, co-financed by FEDER, under the Partnership Agreement PT2020. The authors also acknowledge the support of the Institute of Nanoscience and Nanotechnology under the project ART (2018). | por |
dc.language.iso | eng | por |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | por |
dc.rights | openAccess | por |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | por |
dc.subject | diabetes mellitus | por |
dc.subject | animal models | por |
dc.subject | in vivo | por |
dc.subject | administration routes | por |
dc.title | Sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndromestrategies for in vivo administration: Part-II | por |
dc.type | article | - |
dc.peerreviewed | yes | por |
dc.relation.publisherversion | https://www.mdpi.com/journal/jcm | por |
dc.comments | CEB52044 | por |
oaire.citationIssue | 9 | por |
oaire.citationVolume | 8 | por |
dc.date.updated | 2019-10-07T11:10:31Z | - |
dc.identifier.eissn | 2077-0383 | por |
dc.identifier.doi | 10.3390/jcm8091332 | por |
dc.description.publicationversion | info:eu-repo/semantics/publishedVersion | - |
dc.subject.wos | Science & Technology | por |
sdum.journal | Journal of Clinical Medicine | por |
oaire.version | VoR | por |
Aparece nas coleções: | CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
document_52044_1.pdf | 581,4 kB | Adobe PDF | Ver/Abrir |
Este trabalho está licenciado sob uma Licença Creative Commons